E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Requirement of two-stage unilateral maxillary sinus floor augmentation in case of insufficient bone height in the area of the posterior maxilla, prior to insertion of dental implants. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10061257 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective of the study is to determine the area of newly formed mineralised bone tissue (%) as assessed by histomorphometry 3 or 4 months after sinus floor augmentation (sinus lift) with either MD05 or the comparative product. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives are the safety of MD05, bone quality, radiographic bone gain, area of remaining beta-TCP (%) and uneventful healing. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients requiring two-stage unilateral maxillary sinus floor augmentation (sinus lift) in case of insufficient bone height in the area of the posterior maxilla, prior to insertion of dental implants 2. Residual bone height at the site of planned implantation > 1 mm and < 5 mm 3. Male and female outpatients, 18 to 75 years old 4. Female patients must be infertile (either sterilised or postmenopausal). If a patient's menopausal status at screening is uncertain, levels of follicle stimulating hormone (FSH) should be determined. Patients with an FSH level > 25 IU/l and absence of menstrual bleeding > 6 months will satisfy the definition of postmenopausal status. 5. Patient has given informed consent.
|
|
E.4 | Principal exclusion criteria |
1. Women of childbearing potential, lactating women 2. Participation in another clinical study within 30 days prior to study start 3. Previous participation in this study 4. Last dental extraction (maxilla, posterior to canine) within the last 3 months 5. Failed sinus lift surgery and previous eradictive maxillary sinus surgery (e.g. Caldwell-Luc surgery) 6. Simultaneously bilateral sinus lift 7. Legal incompetence or restricted legal competence 8. Alcoholism, drug dependency, smoking 9. Acute or chronic infection at the application site, e.g., sinusitis 10. Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) 11. Severe allergic rhinitis which requires permanent medication 12. Known intolerance of or hypersensitivity to beta-TCP or rhGDF-5 13. Presence of local or systemic malignant disease or history of local or systemic malignant disease in the past 5 years 14. Patients requiring chemo- or radiotherapy 15. Previous or current radiotherapy of the head 16. Chronic liver disorder (AST and/or ALT over 2 times upper limit of normal) 17. Impaired renal function (serum creatinine over 1.5 times upper limit of normal) 18. Uncontrolled, insulin-dependent diabetes mellitus (HbA1c > 7%) 19. Clinically relevant symptoms of thyroid dysfunction 20. Severe hypertension (RRdiast > 110 mmHg) 21. Clinically relevant cardiovascular disease, e.g., decompensated cardiac insufficiency, haemodynamically relevant heart valve defects, or myocardial infarction during the last three months 22. Systemic bone disease or illness having influence on bone metabolism, e.g. osteogenesis imperfecta, Paget's disease, Ehlers-Danlos disease, osteomalacia, renal osteodystrophia, hyperparathyroidism 23. Clinically relevant blood coagulation disorder, e.g., haemophilia, thrombocytopenia 24. Leukopenia < 3.500 leukocytes/µL 25. Previous (within last 2 months before screening visit) or current treatment with systemic corticosteroids of more than 5 mg/day prednisone equivalent (inhaled glucocorticoids are allowed) 26. Previous or current therapy with drugs having any influence on bone metabolism such as calcitonin or parathormone (as teriparatid) within the last 6 months before screening visit, bisphosphonates or fluoride at least for 30 days within the last 12 months before screening visit 27. Previous (within last 2 months before screening visit) or current treatment with immunosuppressant medication
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy parameter of interest is the proportion of the newly formed mineralised bone (%) as assessed by histomorphometry 3 or 4 months after sinus floor augmentation (sinus lift). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study is defined as the last visit of the last patient undergoing the trial in the participating member state. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |